SEC Form 4 · accession 0001209191-17-031570
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Engelhart
Officer — Chief Financial Officer
Period of report
May 9, 2017
Accepted (ET)
May 11, 2017 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | May 9, 2017 | P | 2,500 | $17.00 | A | 3,576 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects common shares purchased under the Issuer's directed share program in connection with the Issuer's initial public offering.